cp wire

CP Wire Articles

  • The objective response rate was 29 percent (4 of 22 patients)
  • BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumor... read more
Thu, 09/20/18 - 09:47 am
admin
  • Amicus will make an upfront cash payment of $100 million
  • The company also announced closing a $150 million term loan to help finance the acquisition and development costs
  • ... read more
Thu, 09/20/18 - 09:31 am
admin
  • The vaccine was awarded fast-track status by the FDA in October of 2017
  • Pfizer expects to start Phase 3 trials in a few months


Pfizer Inc. (NYSE:PFE) announced on 9/... read more

Thu, 09/20/18 - 09:08 am
admin

MaaT Pharma announced on 9/18/19 the presentation of the analysis of MaaT Pharma’s lead biotherapeutic, MaaT013, demonstrating its drug product characteristics using MaaT Pharma’s proprietary big... read more

Wed, 09/19/18 - 10:57 pm
admin
  • argynx has 8 drugs in development
  • Partners include Abbvie, LEO Pharma, and Staten Biotech

argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company... read more

Wed, 09/19/18 - 09:32 am
admin
  • Cabometyx has orphan drug status in the US
  • Takeda has rights to all indications for Cabometyx in Japan


Exelixis, Inc.  (NASDAQ:EXEL) announced on 9/19/18 that its... read more

Wed, 09/19/18 - 09:16 am
admin
  • Company received positive written response from FDA regarding development plans
  • Resistant P. aeruginosa is designated as ‘Priority 1: Critical’ pathogen by the World Health... read more
Tue, 09/18/18 - 09:07 am
admin
  • Two of the first four evaluable participants showed tumor regressions at the first on-treatment CT scan
  • DPX-Survivac has received fast-track status from FDA
  • It also has... read more
Tue, 09/18/18 - 08:45 am
admin



AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections... read more

Mon, 09/17/18 - 09:08 am
admin
  • AtomWise raised $45 million in Series A in March of 2018
  • Partners Include: Merck, Abbvie, and Bayer


Atomwise Inc., a leader in Artificial Intelligence (AI) for drug... read more

Mon, 09/17/18 - 08:55 am
admin
  • Xelpros is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK)
  • BAK is associated with increased incidence of Ocular Surface Disease (OSD)... read more
Fri, 09/14/18 - 09:48 am
admin
  • In post-hoc analysis, the exposure-adjusted rates of all-cause death and/or hospitalization were reduced approximately 50% in patients receiving Patisiran vs placebo
  • hATTR... read more
Fri, 09/14/18 - 09:35 am
admin
  • Number of shares and price range yet to be determined
  • Allogene has seven products in pre-clinical development and 1 in Ph I trials

Allogene Therapeutics, Inc., a... read more

Fri, 09/14/18 - 09:21 am
admin
  • Inbrija PDUFA goal date extended from October 5, 2018 to January 5, 2019
  • Acorda shares down over 14% in pre-market trading

Acorda Therapeutics, Inc. (Nasdaq:ACOR)... read more

Thu, 09/13/18 - 09:26 am
admin
  • NDX-1017 is intented to halt or reverse Alzheimer's
  • It a completely different mechanism of action than other drug candidates currently in development
  • NDX-1017 addresses... read more
Thu, 09/13/18 - 09:13 am
admin

Microbiome Insights, Inc. is pleased to announce that it will receive a contribution of up to $190,249 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP... read more

Wed, 09/12/18 - 09:30 am
admin
  • Switching to Tremfya at week 28 after inadequate response to Humira, led to a sustained improvement
  • Tremfya is a human monoclonal antibody


The Janssen Pharmaceutical... read more

Wed, 09/12/18 - 09:14 am
admin
  • New investors include Qatar Investment Authority and Redmile Group
  • Funds will be used to advance 5 drug candidates

OncoResponse announced on 9/11/18 the completion of a... read more

Tue, 09/11/18 - 09:08 am
admin

OPKO Health, Inc. (NASDAQ:OPK) has had trading in its common stock halted by The Nasdaq Stock Market, and the exchange has advised OPKO that the halt will continue until the company responds (to... read more

Tue, 09/11/18 - 08:55 am
admin

Pages

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.